Overview

Aliskiren Study of Safety and Efficacy in Senior Hypertensives

Status:
Withdrawn
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the blood pressure lowering efficacy of aliskiren, a combination of aliskiren plus amlodipine, and ramipril in elderly patients with mild to moderate hypertension. It will also compare the long-term safety of an aliskiren-based regimen to a ramipril-based regimen
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine
Hydrochlorothiazide
Ramipril